Whale Team

[Starbeck]

$CELZ on microcapdaily.com

Riveting read from microcapdaily.com

Story source: https://www.microcapdaily.com/the-electrifying-story-of-creative-medical-technology-holdings-inc-otcmkts-celz/122448/

The Exciting Story of Creative Medical Technology Holdings Inc (OTCMKTS: CELZ)
Dave Young
5-6 minutes

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) is an exciting stock that has attracted legions of shareholders who see big things happening here. CELZ flagship CaverStem has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US.

CELZ has runner in its blood and a long history of huge moves skyrocketing from $0.002 in March of last year to highs topping $0.07 per share in August, CELZ loves to run and is a volume leader regularly among the top most traded on the OTCBB.

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) is a commercial-stage biotechnology company focused on Urology and Neurology using stem cell treatments. The company’s team consists of leading international researchers in regenerative medicine with a “science-first” approach to treatments ensuring that all of its treatments are proven to be both safe and effective.

CELZ is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility and related issues. It holds a patent for its erectile dysfunction (“ED”) treatment and was granted a license by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute (“LABIOMED”), for the infertility treatment. It has also filed a patent application focused on physical manifestations of female sexual arousal disorder, as an extension of the work with stem cell therapies for ED.

Creative Medical is currently in the commercial stage of its bone marrow based stem cell treatment for Erectile Dysfunction known as CAVERSTEM, which is being marketed both nationally, and internationally. Earlier this year the Company formed the subsidiary CaverStem International LLC for the purpose of commercializing its erectile dysfunction technology to international physicians.

CaverStem™ received positive reception at international urology conference. Dr. Alexander Gershman stated “I am very impressed by the strong endorsement we have been receiving from colleagues attending the American Urological Association conference. Since beginning to offer the CaverStem™ procedure in December 2017 we have treated multiple patients of which approximately 90% have reported positive improvements. These are all patients for which pharmacological interventions such as Viagra and Cialis do not work. rWhenever a new procedure is introduced to the community, it is fundamentally important to obtain the support of our peers, and to share our findings with our peers. We are enthusiastic by the interest in CaverStem™ by the American and International Urology Community.”

To Find out the inside Scoop on CELZ Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CEO Timothy Warbington said “Now that the AUA conference is over we have immediately began working on vetting the physicians to insure they meet our criteria, negotiating and preparing contracts. Once this is all completed each physician will be scheduled for training on the use of the device and disposables (kits), their CaverStem™ affiliate website will be launched and the CaverStem™ technology will be marketed in each territory.”

Creative Medical Health Technology Holdings is offering the CaverStem™ procedure to selected physicians who qualify according to the Company’s criteria. Approximately 30% of the 30,000,000 patients in the United States suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.

Earlier this year CELZ announced its subsidiary Caverstem International LLC has signed an exclusive contract with Promo Med Russia for the commercialization of its CaverStemTM technology. Professor Dimitri Pushkar MD, Director of Urology at Moscow University, Urologist General of Russia and a decades long colleague of Dr. Alex Gershman was key in the fast paced movement of this agreement and moreover in establishing the practice of the CaverStemTM procedure in Russia. CELZ VP of Sales, Gary Mells is currently in Russia meeting with multiple urologists and officials.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $9.5 million market valuation CELZ is fully reporting OTCBB, has $100k in the treasury, little revenues and $10 million in current liabilities. CELZ is a really exciting Company developing in small caps; CELZ flagship CaverStem has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. The erectile dysfunction market is booming! According to a recent report from ResearchAndMarkets.com, the size of the global erectile dysfunction market is expected to reach $4.25 billion by 2023. We will be updating on CELZ when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CELZ.

Disclosure: we hold no position in CELZ either long or short and we have not been compensated for this article.